HIFU has been a common primary prostate cancer treatment in Europe for quite a while. Currently, in the United States, there are a number of clinical trial sites evaluating HIFU as a primary treatment. Like all other primary treatments there is a significant failure rate causing men to move on to salvage therapy. In Europe [...]
Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial. Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease [...]
Current knowledge makes it very difficult to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa). We are also lacking in novel targets for adjuvant therapies. At the College of Medicine, Mayo Clinic Florida, Jacksonville, FL., researchers evaluated the association of B7-H3 expression in primary PCa [...]
What is the real cost of approved treatments for advanced prostate cancer and how much we should spend? These questions are rippling through the prostate cancer community and the general population. […]
Genetic counseling is common place in the world of breast cancer including the evaluation of the BRCA genes. Prostate and breast cancer increasingly been shown to have a relationship, perhaps all the down to the genetic level. Researchers are now understanding, that like in breast cancer, BRCA1 loss preexisting in small sub-populations of prostate cancer [...]